Published in J Am Coll Cardiol on August 01, 1991
Intra-Cardiac Echocardiography Guided Cardioversion(ICE-CHIP) Study (ICE-CHIP) | NCT00281073
Evidence based medicine: an approach to clinical problem-solving. BMJ (1995) 24.65
Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice. Br J Gen Pract (1995) 6.43
Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ (1992) 5.87
Antithrombotic treatment and atrial fibrillation. BMJ (1992) 5.33
Service provision and use of anticoagulants in atrial fibrillation. BMJ (1995) 4.81
Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol (2009) 3.40
Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. CMAJ (1999) 3.12
Implementation of antithrombotic management in atrial fibrillation. Postgrad Med J (2000) 2.69
Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart (2005) 2.24
Cardiology--II: Treatment of heart failure and atrial fibrillation and arrhythmias. BMJ (1994) 2.01
Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ (2012) 1.68
Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ (2007) 1.29
Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence (2010) 1.26
Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis. PLoS One (2012) 1.24
A community survey of patients with atrial fibrillation: associated disabilities and treatment preferences. Br J Gen Pract (1998) 1.10
Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med (2000) 1.08
Abnormalities in liver function and coagulation profile following the Fontan procedure. Heart (1999) 1.08
Non-rheumatic atrial fibrillation: warfarin or aspirin for all? Br Heart J (1992) 1.07
Influence of decision aids on patient preferences for anticoagulant therapy: a randomized trial. CMAJ (2007) 1.03
The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med (2000) 1.02
Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. J Gen Intern Med (2008) 1.01
Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. J Gen Intern Med (2005) 0.99
Comorbidity associated with atrial fibrillation: a general practice-based study. Br J Gen Pract (2001) 0.98
Reproductive technology and postmenopausal motherhood. CMAJ (1994) 0.94
Commentary: Caution needed in introducing warfarin treatment. BMJ (1995) 0.94
Nonvalvular atrial fibrillation: evidence for a prothrombotic state. CMAJ (1997) 0.94
Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J (2014) 0.92
Anticoagulation in patients with atrial fibrillation. Not safe and not cheap. BMJ (1993) 0.92
Rapid access arrhythmia clinic for the diagnosis and management of new arrhythmias presenting in the community: a prospective, descriptive study. Heart (2004) 0.91
Stroke prevention. Postgrad Med J (1995) 0.91
Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. Ther Adv Drug Saf (2014) 0.89
Atrial fibrillation pearls and perils of management. West J Med (1996) 0.89
Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. Int J Nephrol Renovasc Dis (2009) 0.89
Antithrombotic therapy in atrial fibrillation. Can Fam Physician (1996) 0.88
Dabigatran in atrial fibrillation: pharmacology and clinical trials. J Interv Card Electrophysiol (2011) 0.87
Role of oral anticoagulation in management of atrial fibrillation. Heart (2004) 0.87
Stroke prevention and atrial fibrillation: reasons leading to an inappropriate management. Main results of the SAFE II study. Br J Clin Pharmacol (2004) 0.86
Stroke prevention in atrial fibrillation: concepts and controversies. Curr Cardiol Rev (2012) 0.86
The business case for quality improvement: oral anticoagulation for atrial fibrillation. Circ Cardiovasc Qual Outcomes (2011) 0.86
Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital. Heart (2004) 0.85
Prevention of cardioembolic stroke. Neurotherapeutics (2011) 0.85
New prenatal screening procedures raise spectre of more "wrongful-birth" claims. CMAJ (1995) 0.84
Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. J Am Heart Assoc (2016) 0.83
Advancement in antithrombotics for stroke prevention in atrial fibrillation. J Interv Card Electrophysiol (2008) 0.83
Stroke Prevention in Atrial Fibrillation: Where are We Now? Clin Med Insights Cardiol (2012) 0.82
Use of dose modification schedules is effective for blinding trials of warfarin: evidence from the WASID study. Clin Trials (2008) 0.82
Anticoagulant treatment at a specialized outpatient anticoagulant therapy unit, a descriptive study. Thromb J (2005) 0.81
Anticoagulation and atrial fibrillation. Putting the results of clinical trials into practice. West J Med (1995) 0.81
Fortnightly review: anticoagulation in heart disease. BMJ (1999) 0.81
Limitations to antiarrhythmic drug use in patients with atrial fibrillation. CMAJ (2004) 0.80
Pharmacological management of atrial fibrillation: one, none, one hundred thousand. Cardiol Res Pract (2011) 0.80
Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clin Pharmacol (2016) 0.80
Novel anticoagulants in atrial fibrillation stroke prevention. Ther Adv Chronic Dis (2012) 0.79
Atrial fibrillation and thromboprophylaxis in heart failure: the need for patient-centered approaches to address adherence. Vasc Health Risk Manag (2013) 0.79
Prevalence of oral anticoagulation in atrial fibrillation. Clinics (Sao Paulo) (2014) 0.78
Screening, isolation, and decolonization strategies for vancomycin-resistant enterococci or extended spectrum Beta-lactamase-producing organisms: a systematic review of the clinical evidence and health services impact. CADTH Technol Overv (2013) 0.78
Anticoagulation in atrial fibrillation. Is there a gap in care for ambulatory patients? Can Fam Physician (2004) 0.78
Why is warfarin underutilized in patients with atrial fibrillation? J Interv Card Electrophysiol (2004) 0.77
Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants. PLoS One (2014) 0.77
Bleeding Complications to Long-Term Oral Anticoagulant Therapy. J Thromb Thrombolysis (1994) 0.76
The cumulative risks of prolapsing mitral valve. 40 years of follow-up. Tex Heart Inst J (1994) 0.76
Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulant Therapy Study (AFASAK 2): Methods and Design. J Thromb Thrombolysis (1995) 0.76
How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation? Yonsei Med J (2009) 0.76
AIDS comes to the classroom. CMAJ (1994) 0.75
Peacekeeping stress prompts new approaches to mental-health issues in Canadian military. CMAJ (1994) 0.75
Exploratory Network Meta Regression Analysis of Stroke Prevention in Atrial Fibrillation Fails to Identify Any Interactions with Treatment Effect. PLoS One (2016) 0.75
Atrial fibrillation in women: treatment. Nat Rev Cardiol (2016) 0.75
Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. Circ Arrhythm Electrophysiol (2016) 0.75
Poor adherence to anticoagulation guidelines in patients with non-valvular atrial fibrillation treated in a tertiary cardiology unit. Heart Asia (2015) 0.75
Achieving target international normalization ratio in haemodialysis patients with atrial fibrillation: is it feasible? NDT Plus (2011) 0.75
Atrial fibrillation and stroke: what we know, what's new, and what we should do now. CMAJ (1997) 0.75
Recent advances in cardiology. Postgrad Med J (1994) 0.75
Direct thrombin inhibitors: novel antithrombotics on the horizon in the thromboprophylactic management of atrial fibrillation. Postgrad Med J (2005) 0.75
No stone left unturned at Montreal hospital's clinical research unit. CMAJ (1994) 0.75
Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice. Postgrad Med J (2013) 0.75
Anticoagulation for non-valvular atrial aibrillation - towards a new beginning with ximelagatran. Curr Control Trials Cardiovasc Med (2004) 0.75
Treatment of nonvalvular atrial fibrillation. West J Med (1995) 0.75
Evolution of left atrial thrombus with anticoagulant therapy-follow-up by transesophageal echocardiography. Korean J Intern Med (1995) 0.75
Edoxaban in the evolving scenario of non vitamin K antagonist oral anticoagulants imputed placebo analysis and multiple treatment comparisons. PLoS One (2014) 0.75
Value of transoesophageal echocardiography before DC cardioversion in patients with atrial fibrillation: assessment of embolic risk. Br Heart J (1995) 0.75
Arrhythmias. J R Soc Med (1994) 0.75
The role of coumadin and aspirin in atrial fibrillation. Trans Am Clin Climatol Assoc (1996) 0.75
Anticoagulation in patients with atrial fibrillation. BMJ (1994) 0.75
Stroke Prevention in Atrial Fibrillation. J Atr Fibrillation (2010) 0.75
Warfarin sodium or aspirin therapy to prevent stroke in nonrheumatic atrial fibrillation. Answered and unanswered questions. West J Med (1995) 0.75
LOWERING THE RISK FOR THROMBUS AND STROKE IN ATRIAL FIBRILLATION PATIENTS: Will Dabigatran Replace Warfarin? Clin Med Rev Vasc Health (2013) 0.75
Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants. J Blood Med (2012) 0.75
Evidence-based study on antithrombotic therapy in patients at risk of a stroke with paroxysmal atrial fibrillation. Exp Ther Med (2013) 0.75
[Antithrombotic therapy in atrial fibrillation: when vitamin K antagonists? When aspirin? When heparin? When combinations of anticoagulant and antiplatelet drugs?]. Herzschrittmacherther Elektrophysiol (2009) 0.75
Shared decision making for stroke prevention in atrial fibrillation: study protocol for a randomized controlled trial. Trials (2017) 0.75
Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study. Eur J Clin Pharmacol (2017) 0.75
[Outcome parameters for AF trials--executive summary of an AFNET-EHRA consensus conference]. Herzschrittmacherther Elektrophysiol (2007) 0.75
Anti-thrombotic strategies for patients with atrial fibrillation and heart failure. Heart Fail Rev (2002) 0.75
The Burlington randomized trial of the nurse practitioner. N Engl J Med (1974) 17.02
An assessment of clinically useful measures of the consequences of treatment. N Engl J Med (1988) 13.02
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. JAMA (1999) 12.75
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
The Canadian CT Head Rule for patients with minor head injury. Lancet (2001) 7.91
Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med (1995) 7.83
The Canadian C-spine rule for radiography in alert and stable trauma patients. JAMA (2001) 7.48
Controversy in counting and attributing events in clinical trials. N Engl J Med (1979) 7.25
Randomised clinical trial of strategies for improving medication compliance in primary hypertension. Lancet (1975) 7.22
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med (1995) 6.86
The concept of disease. Br Med J (1979) 6.51
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol (1995) 6.08
A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med (1999) 5.14
Improvement of medication compliance in uncontrolled hypertension. Lancet (1976) 4.84
Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost (2000) 4.81
A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med (1996) 4.70
The Burlington randomized trial of the nurse practitioner: health outcomes of patients. Ann Intern Med (1974) 4.37
A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA (1999) 4.31
Canadian implantable defibrillator study (CIDS) : a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation (2000) 4.12
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med (2001) 3.77
A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med (1993) 3.67
Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet (1994) 3.51
Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet (2000) 3.50
An empirical demonstration of Berkson's bias. J Chronic Dis (1978) 3.48
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science (1984) 3.47
Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst Monogr (1999) 3.45
Effect of bromhexine on ventilatory capacity in patients with a variety of chest diseases. Lancet (1969) 3.34
Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med (2000) 3.32
Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev (2007) 3.28
The Ottawa patient decision aids. Eff Clin Pract (1999) 3.22
Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med (1982) 3.16
Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials (1999) 2.99
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med (1985) 2.99
Evidence-based medicine and the practicing clinician. J Gen Intern Med (1999) 2.99
The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet (1989) 2.97
Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med (1979) 2.91
Cost-effectiveness of magnetic resonance-guided focused ultrasound surgery for treatment of uterine fibroids. BJOG (2008) 2.89
Significance testing to establish equivalence between treatments, with special reference to data in the form of 2X2 tables. Biometrics (1977) 2.87
Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest (1992) 2.81
Variation in emergency department use of cervical spine radiography for alert, stable trauma patients. CMAJ (1997) 2.79
Standardization of inhalation provocation tests: two techniques of aerosol generation and inhalation compared. Am Rev Respir Dis (1981) 2.75
Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. N Engl J Med (1996) 2.69
Antithrombotic therapy in atrial fibrillation. Chest (2001) 2.62
THE PERSONNEL AND PRACTICE OF MEDICINE IN TUDOR AND STUART ENGLAND PART I. THE PROVINCES. Med Hist (1962) 2.55
Clinical recommendations using levels of evidence for antithrombotic agents. Chest (1995) 2.52
Multicentre trial to introduce the Ottawa ankle rules for use of radiography in acute ankle injuries. Multicentre Ankle Rule Study Group. BMJ (1995) 2.50
Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med (1998) 2.49
The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol (1999) 2.44
Perioperative allogeneic blood transfusion does not cause adverse sequelae in patients with cancer: a meta-analysis of unconfounded studies. Br J Surg (1998) 2.44
Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet (1988) 2.44
The rational clinical examination. Does this patient have a clinically important carotid bruit? JAMA (1993) 2.38
N of 1 randomized trials for investigating new drugs. Control Clin Trials (1990) 2.37
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Hypertrophic sternal scars: silicone gel sheet versus Kenalog injection treatment. Plast Reconstr Surg (1992) 2.29
Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the post-arthroplasty screening study. A randomized, controlled trial. Ann Intern Med (1997) 2.28
Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med (1989) 2.28
Dictated versus database-generated discharge summaries: a randomized clinical trial. CMAJ (1999) 2.28
What is the quality of life for survivors of cardiac arrest? A prospective study. Acad Emerg Med (1999) 2.27
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. Chest (2001) 2.25
Initiating, conducting and maintaining guidelines development programs. CMAJ (1993) 2.24
Antithrombotic therapy in atrial fibrillation. Chest (1992) 2.21
A cumulative meta-analysis of the effectiveness of defibrillator-capable emergency medical services for victims of out-of-hospital cardiac arrest. Ann Emerg Med (1999) 2.19
Warfarin for atrial fibrillation. The patient's perspective. Arch Intern Med (1996) 2.18
Clinical significance of a test for slime production in ventriculoperitoneal shunt infections caused by coagulase-negative staphylococci. J Infect Dis (1987) 2.10
Antithrombotic therapy in atrial fibrillation. Chest (1995) 2.08
Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med (1999) 2.07
How should results from completed studies influence ongoing clinical trials? The CAFA Study experience. Ann Intern Med (1991) 2.06
Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: the Canadian Implantable Defibrillator Study. Circulation (2000) 2.05
Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol (1988) 1.93
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br (2009) 1.91
Recombinant 25-kDa CD23 and interleukin 1 alpha promote the survival of germinal center B cells: evidence for bifurcation in the development of centrocytes rescued from apoptosis. Eur J Immunol (1991) 1.82
Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med (2001) 1.82
Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med (1991) 1.81
Depression and risk of sudden cardiac death after acute myocardial infarction: testing for the confounding effects of fatigue. Psychosom Med (2000) 1.80
When and how to assess fast-changing technologies: a comparative study of medical applications of four generic technologies. Health Technol Assess (1997) 1.79
CD23: a multi-functional receptor/lymphokine? Immunol Today (1989) 1.76
Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2000) 1.71
Cost-effectiveness of the implantable cardioverter-defibrillator: results from the Canadian Implantable Defibrillator Study (CIDS). Circulation (2001) 1.70
The consent form as a possible cause of side effects. Clin Pharmacol Ther (1987) 1.68